Edgewise announces positive sevasemten data; FDA provides clear path to first Becker therapy

Edgewise Therapeutics, Inc.

MESA OLE: 99% enrollment (85 participants); NSAA scores improved 0.8 pts over 18 months, diverging from natural history declines.
FDA Type C: NSAA endorsed for traditional approval; CANYON alone insufficient; GRAND CANYON may serve as single pivotal study.
GRAND CANYON on track for topline data Q4 2026; highly powered to show NSAA difference vs placebo over 18 months.
Duchenne Phase 2 LYNX/FOX: 10 mg dose selected for Phase 3; well-tolerated; FOX suggests slower decline in post-gene therapy patients.
Plans to meet FDA Q4 2025 for Phase 3 Duchenne design; pivotal study initiation expected in 2026.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.